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TheAmerican Psychiatric Association PracticeGuideline
on the Use of Antipsychotics to Treat Agitation or
Psychosis in Patients With Dementia
Victor I. Reus, M.D., Laura J. Fochtmann, M.D., M.B.I., A. Evan Eyler, M.D., M.P.H., Donald M. Hilty, M.D.,
Marcela Horvitz-Lennon, M.D., M.P.H., Michael D. Jibson, Ph.D., M.D., Oscar L. Lopez, M.D.,
Jane Mahoney, Ph.D., R.N., PMHCNS-BC, Jagoda Pasic, M.D., Ph.D., Zaldy S. Tan, M.D., M.P.H., Cheryl D. Wills, M.D.,
Richard Rhoads, M.D., Joel Yager, M.D.
At its December 2015 meeting, The APA Board of Trustees
approved the APA Practice Guideline Writing Group’s
“Practice Guideline on the Use of Antipsychotics to Treat
Agitation or Psychosis in Patients With Dementia.” [The full
guideline is available at http://psychiatryonline.org/doi/
book/10.1176/appi.books.9780890426807]
INTRODUCTION
The goal of this guideline is to improve the care of patients
with dementia who are exhibiting agitation or psychosis. More
specifically, this guideline focuses on the judicious use of anti-
psychotic medications when agitation or psychosis occurs in
association with dementia and does not review evidence for or
focus on other pharmacological interventions. The guideline is
intended to apply to individuals with dementia in all settings of
care as well as to care delivered by generalist and specialist
clinicians. Recommendations regarding treatment with anti-
psychotic medications are not intended to apply to individuals
who are receiving antipsychotic medication for another in-
dication (e.g., chronic psychotic illness) or individuals who are
receiving an antipsychotic medication in an urgent context.
Expert consensus suggests that use of an antipsychotic
medication in individuals with dementia can be appropriate,
particularly in individuals with dangerous agitation or psy-
chosis, and can minimize the risk of violence, reduce patient
distress, improve patient’s quality of life, and reduce caregiver
burden.However, inclinical trials, thebenefitsofantipsychotic
medications are at best small (Corbett et al., 2014; Kales et al.,
2015) whether assessed through placebo-controlled trials,
head-to-headcomparisontrials,ordiscontinuationtrials.There
is also consistent evidence that antipsychotics are associated
with clinically significant adverse effects, including mortality.
Consequently, decisions about the treatment of psychosis or
agitation in an individualwithdementiawill be anoutgrowthof
the initial assessment and an understanding of the goals and
preferencesof thepatient (if clinically feasible)andthepatient’s
surrogate decisionmaker (if relevant)with input fromfamily or
others involved with the patient. Such decisions will also need
to balance the potential benefits and harms of a particular
intervention as compared to other therapeutic options for the
individual patient. The full text of the practice guideline in-
cludes a detailed description of expert consensus findings and
research evidence related to effects of antipsychotic medica-
tion in individuals with dementia. It also describes aspects of
guideline implementation that are relevant to individual pa-
tients’ circumstances and clinical presentation.
Overview of the Development Process
Since the 2011 publication of the Institute of Medicine re-
port, Clinical Practice Guidelines We Can Trust, there has
beenan increasing focusonusing clearly defined, transparent
processes for rating the quality of evidence and the strength
of the overall body of evidence in systematic reviews of
the scientific literature. This guideline was developed using
a process intended to be consistent with the recommen-
dations of the Institute of Medicine (2011), the Principles for
the Development of Specialty Society Clinical Guidelines of
the Council of Medical Specialty Societies (2012) and the
requirements of the Agency for Healthcare Research and
Quality (AHRQ) for inclusion of a guideline in the National
Guidelines Clearinghouse. Parameters used for the guide-
lines’ systematic review are included with the full text of the
guideline; the development process is fully described in
the following document available on the American Psychi-
atric Association (APA)website: http://www.psychiatry.org/
File%20Library/Psychiatrists/Practice/Clinical%20Practice
%20Guidelines/Guideline-Development-Process.pdf. To sup-
plement the expertise of members of the guideline work group,
we used a “snowball” survey methodology (Yager 2014) to
identify experts on the treatment of agitation or psychosis in
individuals with dementia. Results of this expert survey are
included in the Appendix of the full practice guideline.
Rating the Strength of Research Evidence and
Recommendations
The guideline recommendations are rated using GRADE
(Grading of Recommendations Assessment, Development and
Evaluation),whichisusedbymultipleprofessionalorganizations
around the world to develop practice guideline recommendations
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(Guyatt et al., 2013).With the GRADE approach, the strength
of a guideline statement reflects the level of confidence that
potential benefits of an intervention outweigh the potential
harms(Andrewsetal., 2013).This levelofconfidence is informed
by available evidence, which includes evidence from clinical
trials as well as expert opinion and patient values and prefer-
ences.Evidencefor thebenefitofaparticular interventionwithin
a specific clinical context is identified through systematic review
and is then balanced against the evidence for harms. In this
regard, harms are broadly defined andmight include direct and
indirect costsof the intervention (includingopportunitycosts) as
well as potential for adverse effects from the intervention.
Whenever possible,wehave followed the admonition to current
guideline development groups to avoid using words such as
“might” or “consider” in drafting these recommendations as they
can be difficult for clinicians to interpret (Shiffman et al., 2005).
As described under Guideline Development Process, each
final rating is a consensus judgment of the authors of the
guideline and is endorsed by the APA Board of Trustees.
A “recommendation” (denoted by the numeral 1 after the
guideline statement) indicates confidence that the benefits
of the intervention clearly outweigh harms. A “suggestion”
(denoted by the numeral 2 after the guideline statement)
indicates uncertainty (i.e., the balance of benefits and harms
is difficult to judge, or either the benefits or the harms are
unclear). Each guideline statement also has an associated
rating for the “strength of supporting research evidence.”
Three ratings are used–high, moderate, and low (denoted by
the letters A, B, and C, respectively)–and reflect the level of
confidence that the evidence for a guideline statement re-
flects a true effect based on consistency of findings across
studies, directness of the effect on a specific health outcome,
and precision of the estimate of effect and risk of bias in
available studies (Agency for Healthcare Research and
Quality 2014; Balshem et al., 2011; Guyatt et al., 2006).
It is well recognized that there are guideline topics and
clinical circumstances for which high quality evidence from
clinical trials is not possible or is unethical to obtain (Council of
MedicalSpecialtySocieties,2012).Forexample,manyquestions
need to be asked as part of an assessment and inquiring about a
particular symptom or element of the history cannot be sepa-
rated out for study as a discrete intervention. It would also be
impossible to separate changes in outcome due to assess-
ment from changes in outcomes due to ensuing treatment.
Research on psychiatric assessments and some psychiatric
interventions can also be complicated by multiple con-
founding factors suchas the interactionbetween theclinician
and the patient or the patient’s unique circumstances and
experiences. For these and other reasons, many topics cov-
ered in this guideline have relied on forms of evidence such
as consensus opinions of experienced clinicians or indirect
findings from observational studies rather than being based
on research from randomized trials. The GRADE working
group and guidelines developed by other professional or-
ganizations have noted that a strong recommendationmay be
appropriate even in the absence of research evidence when
sensible alternatives do not exist (Andrews et al., 2013; Brito
et al, 2013; Djulbegovic et al., 2009; Hazlehurst et al., 2013).
Proper Use of Guidelines
The APA Practice Guidelines are assessments of current
scientific and clinical information provided as an educational
service. The guidelines 1) should not be considered as a
statement of the standard of care or inclusive of all proper
treatments ormethods of care; 2) are not continually updated
andmay not reflect themost recent evidence, as newevidence
may emerge between the time information is developed and
when the guidelines are published or read; 3) address only
the question(s) or issue(s) specifically identified; 4) do not
mandate any particular course of medical care; 5) are not
intended to substitute for the independent professional judg-
ment of the treating provider; and 6) do not account for in-
dividual variation amongpatients. As such, it is not possible to
draw conclusions about the effects of omitting a particular
recommendation, either in general or for a specific patient.
Furthermore, adherence to these guidelines will not ensure a
successful outcome for every individual, nor should these
guidelines be interpreted as including all proper methods of
evaluation and care or excluding other acceptablemethods of
evaluation and care aimed at the same results. The ultimate
recommendation regarding a particular assessment, clinical
procedure, or treatment planmust bemadeby the clinician in
light of the psychiatric evaluation, other clinical data, and the
diagnostic and treatment options available. Such recom-
mendations should bemade in collaborationwith the patient,
whenever possible, and incorporate the patient’s personal
and sociocultural preferences and values in order to enhance
the therapeutic alliance, adherence to treatment, and treat-
ment outcomes. For all of these reasons, APAcautions against
the use of guidelines in litigation. Use of these guidelines is
voluntary. APA provides the guidelines on an “as is” basis,
and makes no warranty, expressed or implied, regarding
them. APA assumes no responsibility for any injury or dam-
age to persons or property arising out of or related to any use
of the guidelines or for any errors or omissions.
GUIDELINE STATEMENTS
Assessment of Behavioral/Psychological Symptoms of Dementia
Statement 1. APA recommends that patients with dementia1
be assessed for the type, frequency, severity, pattern, and
timing of symptoms. (1C)
Statement 2. APA recommends that patients with dementia
be assessed for pain and other potentially modifiable contrib-
utors to symptoms as well as for factors, such as the subtype of
dementia, that may influence choices of treatment. (1C)
1Throughout thisguideline,weuse thetermdementia,whichwasused in the
evidence thatwas considered in developing these recommendations. These
recommendations are also meant to apply to individuals with major neu-
rocognitive disorder, as defined in the American Psychiatric Association’s
Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM–5).
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Statement 3. APA recommends that in patients with de-
mentia with agitation or psychosis, response to treatment be
assessed with a quantitative measure. (1C)
Development of a Comprehensive Treatment Plan
Statement 4. APA recommends that patients with dementia
have a documented comprehensive treatment plan that in-
cludes appropriate person-centered nonpharmacological and
pharmacological interventions, as indicated. (1C)
Assessment of Benefits and Risks of Antipsychotic Treatment
for the Patient
Statement 5. APA recommends that nonemergency anti-
psychotic medication should only be used for the treatment of
agitation or psychosis in patients with dementia when symp-
toms are severe, are dangerous, and/or cause significant dis-
tress to the patient. (1B)
Statement 6. APA recommends reviewing the clinical re-
sponse to nonpharmacological interventions prior to non-
emergency use of an antipsychotic medication to treat
agitation or psychosis in patients with dementia. (1C)
Statement 7. APA recommends that before nonemergency
treatment with an antipsychotic is initiated in patients with
dementia, the potential risks and benefits from antipsychotic
medication be assessed by the clinician and discussed with the
patient (if clinically feasible) as well as with the patient’s sur-
rogate decision maker (if relevant) with input from family or
others involved with the patient. (1C)
Dosing, Duration and Monitoring of Antipsychotic Treatment
Statement 8. APA recommends that if a risk/benefit assessment
favors the use of an antipsychotic for behavioral/psychological
symptoms in patients with dementia, treatment should be initi-
ated at a lowdose to be titratedup to theminimumeffective dose
as tolerated. (1B)
Statement 9. APA recommends that if a patient with de-
mentia experiences a clinically significant side effect of an-
tipsychotic treatment, the potential risks and benefits of
antipsychoticmedication should be reviewedby the clinician
to determine if tapering and discontinuing of the medication
is indicated. (1C)
Statement 10. APA recommends that in patients with de-
mentia with agitation or psychosis, if there is no clinically
significant responseafter a4-week trial of anadequatedoseof
an antipsychotic drug, the medication should be tapered and
withdrawn. (1B)
Statement 11. APA recommends that in a patient who has
shown a positive response to treatment, decision making
about possible tapering of antipsychotic medication should
be accompanied by a discussion with the patient (if clinically
feasible) as well as with the patient’s surrogate decision
maker (if relevant) with input from family or others involved
with the patient. The aim of such a discussion is to elicit their
preferences and concerns and to review the initial goals,
observed benefits and side effects of antipsychotic treatment,
and potential risks of continued exposure to antipsychotics,
as well as past experience with antipsychotic medication
trials and tapering attempts. (1C)
Statement 12. APA recommends that in patients with
dementia who show adequate response of behavioral/
psychological symptoms to treatment with an antipsychotic
drug, an attempt to taper and withdraw the drug should be
made within 4 months of initiation, unless the patient ex-
perienced a recurrence of symptoms with prior attempts at
tapering of antipsychotic medication. (1C)
Statement 13. APA recommends that in patients with de-
mentia whose antipsychotic medication is being tapered,
assessment of symptoms should occur at least monthly during
the taper and for at least 4 months after medication dis-
continuation to identify signs of recurrence and trigger a
reassessment of the benefits and risks of antipsychotic
treatment. (1C)
Use of Specific Antipsychotic Medications, Depending on
Clinical Context
Statement 14. APA recommends that in the absence of de-
lirium, if nonemergency antipsychotic medication treatment
is indicated, haloperidol should not be used as a first-line
agent. (1B)
Statement 15. APA recommends that in patients with de-
mentia with agitation or psychosis, a long-acting injectable
antipsychotic medication should not be utilized unless it
is otherwise indicated for a co-occurring chronic psychotic
disorder. (1B)
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